Survival analysis for AdVerse events with VarYing follow-up times (SAVVY)-estimation of adverse event risks.

Aalen-Johansen estimator Adverse events Competing events Drug safety Incidence density Incidence proportion Kaplan-Meier estimator

Journal

Trials
ISSN: 1745-6215
Titre abrégé: Trials
Pays: England
ID NLM: 101263253

Informations de publication

Date de publication:
29 Jun 2021
Historique:
received: 08 09 2020
accepted: 04 06 2021
entrez: 30 6 2021
pubmed: 1 7 2021
medline: 2 7 2021
Statut: epublish

Résumé

The SAVVY project aims to improve the analyses of adverse events (AEs), whether prespecified or emerging, in clinical trials through the use of survival techniques appropriately dealing with varying follow-up times and competing events (CEs). Although statistical methodologies have advanced, in AE analyses, often the incidence proportion, the incidence density, or a non-parametric Kaplan-Meier estimator are used, which ignore either censoring or CEs. In an empirical study including randomized clinical trials from several sponsor organizations, these potential sources of bias are investigated. The main purpose is to compare the estimators that are typically used to quantify AE risk within trial arms to the non-parametric Aalen-Johansen estimator as the gold-standard for estimating cumulative AE probabilities. A follow-up paper will consider consequences when comparing safety between treatment groups. Estimators are compared with descriptive statistics, graphical displays, and a more formal assessment using a random effects meta-analysis. The influence of different factors on the size of deviations from the gold-standard is investigated in a meta-regression. Comparisons are conducted at the maximum follow-up time and at earlier evaluation times. CEs definition does not only include death before AE but also end of follow-up for AEs due to events related to the disease course or safety of the treatment. Ten sponsor organizations provided 17 clinical trials including 186 types of investigated AEs. The one minus Kaplan-Meier estimator was on average about 1.2-fold larger than the Aalen-Johansen estimator and the probability transform of the incidence density ignoring CEs was even 2-fold larger. The average bias using the incidence proportion was less than 5%. Assuming constant hazards using incidence densities was hardly an issue provided that CEs were accounted for. The meta-regression showed that the bias depended mainly on the amount of censoring and on the amount of CEs. The choice of the estimator of the cumulative AE probability and the definition of CEs are crucial. We recommend using the Aalen-Johansen estimator with an appropriate definition of CEs whenever the risk for AEs is to be quantified and to change the guidelines accordingly.

Sections du résumé

BACKGROUND BACKGROUND
The SAVVY project aims to improve the analyses of adverse events (AEs), whether prespecified or emerging, in clinical trials through the use of survival techniques appropriately dealing with varying follow-up times and competing events (CEs). Although statistical methodologies have advanced, in AE analyses, often the incidence proportion, the incidence density, or a non-parametric Kaplan-Meier estimator are used, which ignore either censoring or CEs. In an empirical study including randomized clinical trials from several sponsor organizations, these potential sources of bias are investigated. The main purpose is to compare the estimators that are typically used to quantify AE risk within trial arms to the non-parametric Aalen-Johansen estimator as the gold-standard for estimating cumulative AE probabilities. A follow-up paper will consider consequences when comparing safety between treatment groups.
METHODS METHODS
Estimators are compared with descriptive statistics, graphical displays, and a more formal assessment using a random effects meta-analysis. The influence of different factors on the size of deviations from the gold-standard is investigated in a meta-regression. Comparisons are conducted at the maximum follow-up time and at earlier evaluation times. CEs definition does not only include death before AE but also end of follow-up for AEs due to events related to the disease course or safety of the treatment.
RESULTS RESULTS
Ten sponsor organizations provided 17 clinical trials including 186 types of investigated AEs. The one minus Kaplan-Meier estimator was on average about 1.2-fold larger than the Aalen-Johansen estimator and the probability transform of the incidence density ignoring CEs was even 2-fold larger. The average bias using the incidence proportion was less than 5%. Assuming constant hazards using incidence densities was hardly an issue provided that CEs were accounted for. The meta-regression showed that the bias depended mainly on the amount of censoring and on the amount of CEs.
CONCLUSIONS CONCLUSIONS
The choice of the estimator of the cumulative AE probability and the definition of CEs are crucial. We recommend using the Aalen-Johansen estimator with an appropriate definition of CEs whenever the risk for AEs is to be quantified and to change the guidelines accordingly.

Identifiants

pubmed: 34187527
doi: 10.1186/s13063-021-05354-x
pii: 10.1186/s13063-021-05354-x
pmc: PMC8244188
doi:

Types de publication

Journal Article Meta-Analysis

Langues

eng

Sous-ensembles de citation

IM

Pagination

420

Références

N Engl J Med. 2005 Nov 3;353(18):1977-9
pubmed: 16267336
Res Synth Methods. 2016 Sep;7(3):282-93
pubmed: 26387882
Pharm Stat. 2016 Jul;15(4):297-305
pubmed: 26929180
J Clin Epidemiol. 2016 Dec;80:135-136
pubmed: 27492787
Lancet Oncol. 2016 May;17(5):663-70
pubmed: 27083333
Ann Intern Med. 2004 Nov 16;141(10):781-8
pubmed: 15545678
Pharm Stat. 2019 Mar;18(2):166-183
pubmed: 30458579
Pharm Stat. 2016 Jul;15(4):292-6
pubmed: 26928768
N Engl J Med. 2017 Mar 16;376(11):1086-1087
pubmed: 28296608
Drug Inf J. 1987;21(1):9-20
pubmed: 10281640
Stat Med. 2009 Mar 15;28(6):1028-39
pubmed: 19152356
BMJ Open. 2020 Jun 11;10(6):e036875
pubmed: 32532777
Lancet. 2002 May 11;359(9318):1686-9
pubmed: 12020548
N Engl J Med. 2017 Aug 31;377(9):829-838
pubmed: 28586279
Trials. 2019 Aug 8;20(1):485
pubmed: 31395087
Pharm Stat. 2021 May 18;:
pubmed: 34002935
Biom J. 2021 Mar;63(3):650-670
pubmed: 33145854
Biom J. 2020 May;62(3):658-669
pubmed: 31756032

Auteurs

Regina Stegherr (R)

Institute of Statistics, Ulm University, Ulm, Germany.

Claudia Schmoor (C)

Clinical Trials Unit, Faculty of Medicine and Medical Center, University of Freiburg, Freiburg im Breisgau, Germany.

Jan Beyersmann (J)

Institute of Statistics, Ulm University, Ulm, Germany.

Kaspar Rufibach (K)

F. Hoffmann-La Roche, Basel, Switzerland.

Valentine Jehl (V)

Novartis Pharma AG, Basel, Switzerland.

Andreas Brückner (A)

Novartis Pharma AG, Basel, Switzerland.

Lewin Eisele (L)

Janssen-Cilag GmbH, Neuss, Germany.

Thomas Künzel (T)

F. Hoffmann-La Roche, Basel, Switzerland.

Katrin Kupas (K)

Bristol-Myers-Squibb GmbH & Co. KGaA, München, Germany.

Frank Langer (F)

Lilly Deutschland GmbH, Bad Homburg, Germany.

Friedhelm Leverkus (F)

Pfizer, Berlin, Germany.

Anja Loos (A)

Merck KGaA, Darmstadt, Germany.

Christiane Norenberg (C)

Bayer AG, Wuppertal, Germany.

Florian Voss (F)

Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany.

Tim Friede (T)

Department of Medical Statistics, University Medical Center Göttingen, Humboldtallee 32, Göttingen, 37073, Germany. tim.friede@med.uni-goettingen.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH